Recruiting studies: Langerhans Cell Histiocytosis Lch

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

Vinblastine/Prednisone Versus Single Therapy With Cytarabine for Langerhans Cell Histiocytosis (LCH)
Phase 3 · 11 location(s) · Baylor College of Medicine · NCT02670707 Optimization of the Time and Dosage of Trametinib in BRAF Negative Juvenile Patients
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943224 Targeted Approach to Langerhans Cell Histiocytosis (LCH) Using MEK Inhibitor, Trametinib
Phase 2 · 1 location(s) · Cook Children's Health Care System · NCT06582745 Registry for Patients With Erdheim-Chester Disease and Other Histiocytoses
Phase N/A · 1 location(s) · Memorial Sloan Kettering Cancer Center · NCT03329274 Modified LCH-III Regimen With or Without Luvometinib for Multisystem Pediatric Langerhans Cell Histiocytosis
NA · 11 location(s) · West China Second University Hospital · NCT07431060 Mirdametinib in Histiocytic Disorders
Phase 2 · 1 location(s) · Children's Hospital Medical Center, Cincinnati · NCT06153173 Luvometinib in Pediatric SS-LCH With Special-site Single/Multifocal Bone Lesions
NA · 11 location(s) · West China Second University Hospital · NCT07371182 Histiocytic Disorder Follow-up Study
Phase N/A · 1 location(s) · University of Alabama at Birmingham · NCT05915208 Q702 for the Treatment of Patients With Hematologic Malignancies
Phase 1 · 2 location(s) · Mayo Clinic · NCT06712810 Efficacy and Safety of Low-Dose Cytarabine Combined With Thalidomide in Adult Patients With Untreated LCH
Phase 2 · 1 location(s) · Cancer Institute and Hospital, Chinese Academy of Medical Sc · NCT07187193 Adult Pulmonary Langerhans Cell Histiocytosis: a National Registry-based Prospective Cohort Study
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT04665674 Cobimetinib in Refractory Langerhans Cell Histiocytosis (LCH), and Other Histiocytic Disorders
Phase 2 · 12 location(s) · Carl Allen · NCT04079179 Optimization of the Time and Dosage of Vemurafenib in BRAF Positive Juvenile Patients With Refractory Histiocytosis
Phase 2 · 1 location(s) · Anna Raciborska · NCT04943198 Biomarkers for Diagnostic, Prognostic and of Response to Treatment in Adult Langerhans Cell Histiocytosis
Phase N/A · 1 location(s) · Assistance Publique - Hôpitaux de Paris · NCT06197204 Real-world Study of Darafenib or Trametinib and Clofarabine for High-risk/Recurrent/Refractory Langerhans Cell Histiocyt
Phase 2 · 1 location(s) · West China Second University Hospital · NCT07022834 Oral Prednisone in Treating LCH of Bone in Childhood and Adolescence
Phase 2 · 1 location(s) · Shanghai Changzheng Hospital · NCT06078969 Project: Every Child for Younger Patients With Cancer
Phase N/A · 278 location(s) · Children's Oncology Group · NCT02402244 To Evaluate the Efficacy, Safety, and PK Characteristics of FCN-159 in Pediatric Patients With Refractory/Recurrent LCH
Phase 2 · 11 location(s) · Shanghai Fosun Pharmaceutical Industrial Development Co. Ltd · NCT05997602 Determination of Molecular Status, the Efficacy and Safety of Fluorodeoxyglucose in PET-CT Imaging
Phase 3 · 1 location(s) · Anna Raciborska · NCT04943211 A Study With Tovorafenib (DAY101) as a Treatment Option for Progressive, Relapsed, or Refractory Langerhans Cell Histioc
Phase 2 · 119 location(s) · National Cancer Institute (NCI) · NCT05828069

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.